azathioprine + sirolimus
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Delayed Graft Function
Conditions
Delayed Graft Function, Acute Graft Rejection
Trial Timeline
Apr 1, 2002 → Aug 1, 2011
NCT ID
NCT00321906About azathioprine + sirolimus
azathioprine + sirolimus is a approved stage product being developed by Astellas Pharma for Delayed Graft Function. The current trial status is completed. This product is registered under clinical trial identifier NCT00321906. Target conditions include Delayed Graft Function, Acute Graft Rejection.
What happened to similar drugs?
2 of 3 similar drugs in Delayed Graft Function were approved
Approved (2) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00321906 | Approved | Completed |
Competing Products
8 competing products in Delayed Graft Function
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lemborexant + Placebo | Eisai | Approved | 50 |
| Belatacept + Everolimus | Bristol Myers Squibb | Phase 1 | 21 |
| Belatacept + Calcineurin Inhibitor | Bristol Myers Squibb | Phase 2 | 31 |
| ARGX-117 | Argenx | Phase 2 | 36 |
| BG9418 (interferon beta-1a) | Biogen | Pre-clinical | 23 |
| Desflurane + Propofol | Baxter | Approved | 40 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 41 |
| TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent | Tonix Pharmaceuticals | Phase 1 | 11 |